ZAI Lab of Shanghai has dosed the first subject in a Phase 1 study of ZL-2102, a novel anti-inflammatory drug, as a treatment for chronic respiratory diseases. The trial is being conducted in Australia among healthy volunteers. ZAI Lab in-licensed global rights to two novel compounds from Sanofi last year, both of which are potential treatments for respiratory diseases (see story). At the time, the drugs had already completed their pre-clinical development. ZL-2102 is the first to begin a clinical trial.
Help employers find you! Check out all the jobs and post your resume.
